Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Panther Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The portfolio's current prosecution is focused on a single point of contact within the patent office, which simplifies the coordination of legal arguments and evidence.
The busiest examiner, GOTFREDSON, GAREN, is responsible for 1 pending office action. This 1 action represents the total pending workload for the company. Because there is only 1 pending office action, the practitioner can focus exclusively on the specific arguments and evidence required by GOTFREDSON, GAREN. This allows for a highly targeted response that addresses the examiner's specific technical and procedural concerns directly.
The involvement of 1 distinct art unit provides a consistent framework for the 1 pending office action. Practitioners should leverage this focus to resolve the 1 outstanding matter efficiently. The absence of multiple pending actions simplifies the management of the portfolio's immediate legal objectives. By focusing on the 1 distinct examiner, the legal team can develop a precise strategy to advance the 1 pending office action toward a final disposition.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOTFREDSON, GAREN | 1 | 39.9% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18356925 | TISSUE PENETRATING AND BIODEGRADABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | GOTFREDSON, GAREN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18356925 | TISSUE PENETRATING AND BIODEGRADABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | GOTFREDSON, GAREN | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18356925 | TISSUE PENETRATING AND BIODEGRADABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF | GOTFREDSON, GAREN | 1619 | §102§103§112Other | Final Rejection | — | Pending | Jul 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPanther Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Garen Gotfredson has the most, with 1 of Panther Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
